Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 134 articles:
HTML format
Text format



Single Articles


    February 2017
  1. HA GS, Kim YW, Choi EH, Kim IY, et al
    Factors Associated with the Lack of Adjuvant Chemotherapy Following Curative Surgery for Stage II and III Colon Cancer: A Korean National Cohort Study.
    Anticancer Res. 2017;37:915-922.
    PubMed     Text format     Abstract available


  2. KANEKO M, Ishihara S, Murono K, Sasaki K, et al
    Carbohydrate Antigen 19-9 Predicts Synchronous Peritoneal Carcinomatosis in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:865-870.
    PubMed     Text format     Abstract available


  3. HAGLAND HR, Lea D, Watson MM, Soreide K, et al
    Correlation of Blood T-Cells to Intratumoural Density and Location of CD3+ and CD8+ T-Cells in Colorectal Cancer.
    Anticancer Res. 2017;37:675-683.
    PubMed     Text format     Abstract available


  4. IWATA N, Ishikawa T, Okazaki S, Mogushi K, et al
    Clinical Significance of Methylation and Reduced Expression of the Quaking Gene in Colorectal Cancer.
    Anticancer Res. 2017;37:489-498.
    PubMed     Text format     Abstract available


  5. CHUNG SS, Adekoya D, Enenmoh I, Clarke O, et al
    Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced Telomerase Activity in Colorectal Cancer Cells.
    Anticancer Res. 2017;37:445-453.
    PubMed     Text format     Abstract available


    January 2017

  6. Non-coding RNAs in Colorectal Cancer.
    Anticancer Res. 2017;37:369.
    PubMed     Text format    


  7. PASQUALETTI F, Montrone S, Vivaldi C, Zani M, et al
    Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:315-319.
    PubMed     Text format     Abstract available


  8. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available


  9. PARK M, Sundaramoorthy P, Sim JJ, Jeong KY, et al
    Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
    Anticancer Res. 2017;37:103-114.
    PubMed     Text format     Abstract available


  10. IMAI T, Oue N, Sentani K, Sakamoto N, et al
    KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells.
    Anticancer Res. 2017;37:47-55.
    PubMed     Text format     Abstract available


  11. SANTOS MD, Silva C, Rocha A, Nogueira C, et al
    Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.
    Anticancer Res. 2017;37:281-291.
    PubMed     Text format     Abstract available


  12. ATTENBERGER UI, Ong MM, Rathmann N, Doyon F, et al
    mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer.
    Anticancer Res. 2017;37:215-222.
    PubMed     Text format     Abstract available


  13. RUBIO CA
    Three Pathways of Colonic Carcinogenesis in Rats.
    Anticancer Res. 2017;37:15-20.
    PubMed     Text format     Abstract available


  14. MORIS D, Dimitroulis D, Vernadakis S, Papalampros A, et al
    Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes.
    Anticancer Res. 2017;37:9-14.
    PubMed     Text format     Abstract available


    December 2016
  15. SUZUKI A, Kobayashi R, Fujii H, Iihara H, et al
    Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk.
    Anticancer Res. 2016;36:6527-6533.
    PubMed     Text format     Abstract available


  16. NAGANO Y, Toiyama Y, Okugawa Y, Imaoka H, et al
    MicroRNA-7 Is Associated with Malignant Potential and Poor Prognosis in Human Colorectal Cancer.
    Anticancer Res. 2016;36:6521-6526.
    PubMed     Text format     Abstract available


  17. YEO MK, Lee YM, Seong IO, Choi SY, et al
    Up-regulation of Cytoplasmic CD24 Expression Is Associated with Malignant Transformation but Favorable Prognosis of Colorectal Adenocarcinoma.
    Anticancer Res. 2016;36:6593-6598.
    PubMed     Text format     Abstract available


  18. SHANY S, Sigal-Batikoff I, Lamprecht S
    Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-beta/SMAD Signaling.
    Anticancer Res. 2016;36:6225-6234.
    PubMed     Text format     Abstract available


    November 2016
  19. ICHIHARA H, Okumura M, Matsumoto Y
    Therapeutic Effects of Hybrid Liposomes Against Xenograft Mouse Model of Colorectal Cancer In Vivo Due to Long-term Accumulation.
    Anticancer Res. 2016;36:5875-5882.
    PubMed     Text format     Abstract available


  20. CHIEN CR, Chen WT, Wang HM, Ke TW, et al
    A Comparative Effectiveness Study of Two Oral Chemotherapy Drugs (UFT vs. Capecitabine) in Neoadjuvant Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.
    Anticancer Res. 2016;36:6155-6160.
    PubMed     Text format     Abstract available


    October 2016
  21. ALT M, Truant S, Renaud-Vantroys T, Sequier C, et al
    Bevacizumab Associated with Chemotherapy for Initially Non-resectable Liver Metastases from Colorectal Cancer: a Case-Control Study.
    Anticancer Res. 2016;36:5551-5555.
    PubMed     Text format     Abstract available


  22. SARLINOVA M, Halasa M, Mistuna D, Musak L, et al
    miR-21, miR-221 and miR-150 Are Deregulated in Peripheral Blood of Patients with Colorectal Cancer.
    Anticancer Res. 2016;36:5449-5454.
    PubMed     Text format     Abstract available


  23. YAMAOKA Y, Ikeda M, Ikenaga M, Murakami H, et al
    Anti-metastatic Effect of Short-term Postoperative Anticoagulation for Patients Undergoing Curative Resection of Colorectal Cancer.
    Anticancer Res. 2016;36:5425-5429.
    PubMed     Text format     Abstract available


  24. KODA K, Miyauchi H, Kosugi C, Kaiho T, et al
    Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Anticancer Res. 2016;36:5325-5331.
    PubMed     Text format     Abstract available


  25. ALFAYEZ M, Vishnubalaji R, Alajez NM
    Runt-related Transcription Factor 1 (RUNX1T1) Suppresses Colorectal Cancer Cells Through Regulation of Cell Proliferation and Chemotherapeutic Drug Resistance.
    Anticancer Res. 2016;36:5257-5263.
    PubMed     Text format     Abstract available


  26. ISEKI Y, Shibutani M, Maeda K, Nagahara H, et al
    Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
    Anticancer Res. 2016;36:5145-5151.
    PubMed     Text format     Abstract available


  27. SIDERIS M, Moorhead J, Diaz-Cano S, Bjarnason I, et al
    KRAS Mutant Status, p16 and beta-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.
    Anticancer Res. 2016;36:5315-5324.
    PubMed     Text format     Abstract available


  28. ELZAGHEID A, Emaetig F, Elsaghayer W, Torjman F, et al
    Neurofibromin Expression is Associated with Aggressive Disease and Poor Outcome in Colorectal Carcinoma.
    Anticancer Res. 2016;36:5301-5306.
    PubMed     Text format     Abstract available


  29. BACZYNSKA D, Bombik I, Malicka-Blaszkiewicz M
    beta-Catenin Expression Regulates Cell Migration of Human Colonic Adenocarcinoma Cells Through Gelsolin.
    Anticancer Res. 2016;36:5249-5256.
    PubMed     Text format     Abstract available


  30. TAMPELLINI M, Benedetto S, Rubatto E, Baratelli C, et al
    Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
    Anticancer Res. 2016;36:5163-5170.
    PubMed     Text format     Abstract available


  31. DE FELICE F, Musio D, Benevento I, Magnante A, et al
    Influence of Organ Invasion in Clinical Outcomes for Locally Advanced Rectal Cancer.
    Anticancer Res. 2016;36:5443-5447.
    PubMed     Text format     Abstract available


  32. BISCANIN A, Ljubicic N, Boban M, Balicevic D, et al
    CX43 Expression in Colonic Adenomas and Surrounding Mucosa Is a Marker of Malignant Potential.
    Anticancer Res. 2016;36:5437-5442.
    PubMed     Text format     Abstract available


  33. NONAKA T, Fukuda A, Maekawa K, Nagayoshi S, et al
    Clinical and Oncological Outcomes of Laparoscopic Versus Open Surgery for Advanced Rectal Cancer.
    Anticancer Res. 2016;36:5419-5424.
    PubMed     Text format     Abstract available


  34. RUBIO CA, Schmidt PT
    Gut-associated Lymphoid Tissue (GALT) Carcinoma or Dome Carcinoma?
    Anticancer Res. 2016;36:5385-5387.
    PubMed     Text format     Abstract available


    September 2016
  35. KISS I, Mlcochova J, Bortlicek Z, Poprach A, et al
    Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Anticancer Res. 2016;36:4955-9.
    PubMed     Text format     Abstract available


  36. LIBERALE G, Vankerckhove S, Galdon MG, Larsimont D, et al
    Sentinel Lymph Node Detection by Blue Dye Versus Indocyanine Green Fluorescence Imaging in Colon Cancer.
    Anticancer Res. 2016;36:4853-8.
    PubMed     Text format     Abstract available


  37. PIKOULIS E, Margonis GA, Andreatos N, Sasaki K, et al
    Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
    Anticancer Res. 2016;36:4805-11.
    PubMed     Text format     Abstract available


  38. NAKANISHI M, Kuriu Y, Murayama Y, Arita T, et al
    Usefulness of Reduced Port Surgery for Left Colon Cancer.
    Anticancer Res. 2016;36:4749-52.
    PubMed     Text format     Abstract available


  39. KAWAGUCHI D, Hiroshima Y, Matsuo K, Endo I, et al
    Hepatic Resection After Prehepatectomy Chemotherapy for Metastatic Colorectal Cancer: A Propensity-Matched Analysis.
    Anticancer Res. 2016;36:4725-30.
    PubMed     Text format     Abstract available


  40. RACHAR V, Czejka M, Kitzmueller M, Buchner P, et al
    Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.
    Anticancer Res. 2016;36:4715-23.
    PubMed     Text format     Abstract available


  41. STANKEVICIUS V, Vasauskas G, Noreikiene R, Kuodyte K, et al
    Extracellular Matrix-dependent Pathways in Colorectal Cancer Cell Lines Reveal Potential Targets for Anticancer Therapies.
    Anticancer Res. 2016;36:4559-67.
    PubMed     Text format     Abstract available


  42. TANAKA R, Tomosugi M, Sakai T, Sowa Y, et al
    MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
    Anticancer Res. 2016;36:4537-43.
    PubMed     Text format     Abstract available


  43. LING E, Ringel A, Sigal-Batikoff I, Abu-Freha N, et al
    Human Colorectal Cancer Stage-dependent Global DNA Hypomethylation of Cancer-associated Fibroblasts.
    Anticancer Res. 2016;36:4503-7.
    PubMed     Text format     Abstract available


  44. YUN CW, Yun S, Lee JH, Han YS, et al
    Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan.
    Anticancer Res. 2016;36:4449-58.
    PubMed     Text format     Abstract available


  45. HOLUBEC L, Polivka J Jr, Safanda M, Karas M, et al
    The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.
    Anticancer Res. 2016;36:4421-6.
    PubMed     Text format     Abstract available


  46. DA SILVA FC, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M, et al
    Update on Hereditary Colorectal Cancer.
    Anticancer Res. 2016;36:4399-405.
    PubMed     Text format     Abstract available


  47. SHIN YR, Kim KA, Im S, Hwang SS, et al
    Prediction of KRAS Mutation in Rectal Cancer Using MRI.
    Anticancer Res. 2016;36:4799-804.
    PubMed     Text format     Abstract available


  48. KAWAGUCHI D, Hiroshima Y, Matsuo K, Endo I, et al
    Parenchymal Congestion Is Important for Rapid Regeneration of the Future Liver Remnant Following the ALPPS Procedure.
    Anticancer Res. 2016;36:4731-8.
    PubMed     Text format     Abstract available


  49. ATANASOVA S, Nikolova B, Murayama S, Stoyanova E, et al
    Electroinduced Delivery of Hydrogel Nanoparticles in Colon 26 Cells, Visualized by Confocal Fluorescence System.
    Anticancer Res. 2016;36:4601-6.
    PubMed     Text format     Abstract available


  50. KAPPIL M, Terry MB, Delgado-Cruzata L, Liao Y, et al
    Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4437-41.
    PubMed     Text format     Abstract available


    August 2016
  51. SUEDA T, Sakai D, Kudo T, Sugiura T, et al
    Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Anticancer Res. 2016;36:4299-306.
    PubMed     Text format     Abstract available


  52. MONTAGNANI F, DI Leonardo G, Pino MS, Martella F, et al
    Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
    Anticancer Res. 2016;36:4259-65.
    PubMed     Text format     Abstract available


  53. PLOQUIN A, Zerimech F, Escande F, Adenis A, et al
    Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.
    Anticancer Res. 2016;36:4233-6.
    PubMed     Text format     Abstract available


  54. KUNIZAKI M, Sawai T, Takeshita H, Tominaga T, et al
    Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
    Anticancer Res. 2016;36:4171-5.
    PubMed     Text format     Abstract available


  55. BABA H, Ishikawa T, Mogushi K, Ishiguro M, et al
    Identification of SATB1 as a Specific Biomarker for Lymph Node Metastasis in Colorectal Cancer.
    Anticancer Res. 2016;36:4069-76.
    PubMed     Text format     Abstract available


  56. DJAAFAR S, Dunand-Sautier I, Gonelle-Gispert C, Lacotte S, et al
    Enoxaparin Attenuates Mouse Colon Cancer Liver Metastases by Inhibiting Heparanase and Interferon-gamma-inducible Chemokines.
    Anticancer Res. 2016;36:4019-32.
    PubMed     Text format     Abstract available


  57. ILHAN N, Gungor H, Gul HF, Eroksuz H, et al
    Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer.
    Anticancer Res. 2016;36:3953-9.
    PubMed     Text format     Abstract available


  58. KUMASHIRO R, Konishi K, Chiba T, Akahoshi T, et al
    Integrated Endoscopic System Based on Optical Imaging and Hyperspectral Data Analysis for Colorectal Cancer Detection.
    Anticancer Res. 2016;36:3925-32.
    PubMed     Text format     Abstract available


  59. MEEKS MW, Grace S, Chen Y, Petterchak J, et al
    Synchronous Quadruple Primary Neoplasms: Colon Adenocarcinoma, Collision Tumor of Neuroendocrine Tumor and Schwann Cell Hamartoma and Sessile Serrated Adenoma of the Appendix.
    Anticancer Res. 2016;36:4307-11.
    PubMed     Text format     Abstract available


  60. ETO K, Kosuge M, Ohkuma M, Haruki K, et al
    Comparison of Transumbilical and Conventional Defunctioning Ileostomy in Laparoscopic Anterior Resections for Rectal Cancer.
    Anticancer Res. 2016;36:4139-44.
    PubMed     Text format     Abstract available


  61. PICARDI V, Deodato F, Guido A, Giaccherini L, et al
    Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.
    Anticancer Res. 2016;36:4081-7.
    PubMed     Text format     Abstract available


    July 2016
  62. SHIRAIWA S, Kinugasa T, Kawahara A, Mizobe T, et al
    Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
    Anticancer Res. 2016;36:3781-8.
    PubMed     Text format     Abstract available


  63. YOSHIDA Y, Naito M, Yamada T, Aisu N, et al
    Adoptive Chemoimmunotherapy Using Activated alphabeta T Cells for Stage IV Colorectal Cancer.
    Anticancer Res. 2016;36:3741-6.
    PubMed     Text format     Abstract available


  64. MUKOHYAMA J, Shimono Y, Yamashita K, Sumi Y, et al
    Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells.
    Anticancer Res. 2016;36:3679-86.
    PubMed     Text format     Abstract available


  65. YAMAGUCHI T, Iwasa S, Nagashima K, Ikezawa N, et al
    Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Anticancer Res. 2016;36:3531-6.
    PubMed     Text format     Abstract available


  66. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available


  67. CHUNG YH, Kim D
    Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3beta.
    Anticancer Res. 2016;36:3383-94.
    PubMed     Text format     Abstract available


  68. KANG BW, Jeon HS, Chae YS, Lee SJ, et al
    Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer.
    Anticancer Res. 2016;36:3353-61.
    PubMed     Text format     Abstract available


  69. YAMASAKI K, Matsui T, Hisabe T, Yano Y, et al
    Retrospective Analysis of Growth Speed of 54 Lesions of Colitis-associated Colorectal Neoplasia.
    Anticancer Res. 2016;36:3731-40.
    PubMed     Text format     Abstract available


  70. SAKAUE M, Maeda K, Ohno S, Ito T, et al
    Screening for Identification of Personalized Food to Promote Adiponectin Secretion in Patients with Cancer.
    Anticancer Res. 2016;36:3673-7.
    PubMed     Text format     Abstract available


  71. ALIBERTI C, Carandina R, Sarti D, Mulazzani L, et al
    Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy.
    Anticancer Res. 2016;36:3515-21.
    PubMed     Text format     Abstract available


  72. AKINWANDE O, Scoggins C, Martin RC
    Early Experience with 70-150 mum Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases.
    Anticancer Res. 2016;36:3413-8.
    PubMed     Text format     Abstract available


    June 2016

  73. Laparoscopic Surgery for Colorectal Cancer.
    Anticancer Res. 2016;36:3225.
    PubMed     Text format    


  74. BRADATSCH A, Kornprat P, Bacher H, Cerwenka H, et al
    The Value of Lymph Node Dissection in the Surgery of Colorectal Cancer Liver Metastases.
    Anticancer Res. 2016;36:2993-7.
    PubMed     Text format     Abstract available


  75. HENKENBERENS C, Toklu H, Tamme C, Bruns F, et al
    Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis.
    Anticancer Res. 2016;36:3173-7.
    PubMed     Text format     Abstract available


  76. MIYAMOTO J, Michaud AL, Harandi NK, Kim EJ, et al
    The Role of Image-guided Radiotherapy in the Treatment of Anorectal Cancer Using Prone Belly-board Positioning.
    Anticancer Res. 2016;36:3013-7.
    PubMed     Text format     Abstract available


  77. SODRING M, Gunnes G, Paulsen JE
    Detection and Characterization of Flat Aberrant Crypt Foci (Flat ACF) in the Novel A/J Min/+ Mouse.
    Anticancer Res. 2016;36:2745-50.
    PubMed     Text format     Abstract available


  78. NASIR A, Reising LO, Nedderman DM, Fulford AD, et al
    Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
    Anticancer Res. 2016;36:2683-96.
    PubMed     Text format     Abstract available


  79. HAO X, Xiao H, Ju J, Hewitt SM, et al
    Decreased Expression of Retinoid X Receptors During Human and Azoxymethane-induced Colorectal Carcinogenesis in the Rat.
    Anticancer Res. 2016;36:2659-64.
    PubMed     Text format     Abstract available


    May 2016
  80. OGAWA M, Anan T, Suzuki T, Okuma M, et al
    Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
    Anticancer Res. 2016;36:2505-11.
    PubMed     Text format     Abstract available


  81. KAMADA Y, Murayama Y, Ota U, Takahashi K, et al
    Urinary 5-Aminolevulinic Acid Concentrations as a Potential Tumor Marker for Colorectal Cancer Screening and Recurrence.
    Anticancer Res. 2016;36:2445-50.
    PubMed     Text format     Abstract available


  82. KIM CW, Roh SA, Tak KH, Koh BM, et al
    ZKSCAN3 Facilitates Liver Metastasis of Colorectal Cancer Associated with CEA-expressing Tumor.
    Anticancer Res. 2016;36:2397-406.
    PubMed     Text format     Abstract available


  83. MITSELOU A, Galani V, Skoufi U, Arvanitis DL, et al
    Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/beta-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer.
    Anticancer Res. 2016;36:2271-80.
    PubMed     Text format     Abstract available


  84. HASEGAWA K, Suetsugu A, Nakamura M, Matsumoto T, et al
    Imaging Nuclear-Cytoplasmic Dynamics in Primary and Metastatic Colon Cancer in Nude Mice.
    Anticancer Res. 2016;36:2113-7.
    PubMed     Text format     Abstract available


  85. SADAHIRO S, Suzuki T, Tanaka A, Okada K, et al
    Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer.
    Anticancer Res. 2016;36:2433-40.
    PubMed     Text format     Abstract available


  86. WISNIEWSKI J, Wesolowska O, Sroda-Pomianek K, Paprocka M, et al
    Euphorbia Species-derived Diterpenes and Coumarins as Multidrug Resistance Modulators in Human Colon Carcinoma Cells.
    Anticancer Res. 2016;36:2259-64.
    PubMed     Text format     Abstract available


  87. RADIC J, Kruslin B, Samija M, Ulamec M, et al
    Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease.
    Anticancer Res. 2016;36:2189-96.
    PubMed     Text format     Abstract available


  88. YAMAUCHI K, Kokuryo T, Yokoyama Y, Uehara K, et al
    Prediction of Early Recurrence After Curative Resection of Colorectal Liver Metastasis and Subsequent S-1 Chemotherapy.
    Anticancer Res. 2016;36:2175-9.
    PubMed     Text format     Abstract available


  89. TRESKA V
    Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives.
    Anticancer Res. 2016;36:2065-71.
    PubMed     Text format     Abstract available


    April 2016

  90. Multimodal Treatment of Recurrent Pelvic Colorectal Cancer.
    Anticancer Res. 2016;36:2049.
    PubMed     Text format    


  91. ARITA S, Shirakawa T, Matsushita Y, Shimokawa HK, et al
    Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
    Anticancer Res. 2016;36:1959-66.
    PubMed     Text format     Abstract available


  92. UMEHARA M, Umehara Y, Takahashi K, Murata A, et al
    Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
    Anticancer Res. 2016;36:1949-54.
    PubMed     Text format     Abstract available


  93. RADES D, Bartscht T, Janssen S, Bajrovic A, et al
    Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly.
    Anticancer Res. 2016;36:1829-33.
    PubMed     Text format     Abstract available


  94. HIROSHIMA Y, Matsuo K, Kawaguchi D, Kikuchi Y, et al
    Modified Liver Hanging Maneuver for En-bloc Right-sided Hepatectomy Combined with Total Caudate Lobectomy for Colon-Cancer Liver Metastasis and Hepatocellular Carcinoma.
    Anticancer Res. 2016;36:1729-35.
    PubMed     Text format     Abstract available


  95. CHANG WS, Yueh TC, Tsai CW, Ji HX, et al
    Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotypes to Colorectal Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:1657-1663.
    PubMed     Text format     Abstract available


  96. ABRAMS MJ, Koffer PP, Leonard KL
    The Emerging Non-operative Management of Non-metastatic Rectal Cancer: A Population Analysis.
    Anticancer Res. 2016;36:1699-702.
    PubMed     Text format     Abstract available


  97. KORBER MI, Staribacher A, Ratzenbock I, Steger G, et al
    NFkappaB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.
    Anticancer Res. 2016;36:1631-9.
    PubMed     Text format     Abstract available


  98. FRANCO P, Arcadipane F, Ragona R, Mistrangelo M, et al
    Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Anticancer Res. 2016;36:2027-32.
    PubMed     Text format     Abstract available


  99. SUMRIEN H, Dadnam C, Hewitt J, McCarthy K, et al
    Feasibility of Transanal Minimally Invasive Surgery (TAMIS) for Rectal Tumours and Its Impact on Quality of Life - The Bristol Series.
    Anticancer Res. 2016;36:2005-9.
    PubMed     Text format     Abstract available


  100. TANAKAYA K, Yamaguchi T, Ishikawa H, Hinoi T, et al
    Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
    Anticancer Res. 2016;36:1985-9.
    PubMed     Text format     Abstract available


  101. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  102. FRANCO P, Arcadipane F, Ragona R, Mistrangelo M, et al
    Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Anticancer Res. 2016;36:1943-8.
    PubMed     Text format     Abstract available


  103. NAKANISHI M, Kuriu Y, Murayama Y, Arita T, et al
    A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy.
    Anticancer Res. 2016;36:1851-4.
    PubMed     Text format     Abstract available


  104. ROMANO M, DE Francesco F, Zarantonello L, Ruffolo C, et al
    From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives.
    Anticancer Res. 2016;36:1447-60.
    PubMed     Text format     Abstract available


    March 2016
  105. YIU AJ, Yiu CY
    Biomarkers in Colorectal Cancer.
    Anticancer Res. 2016;36:1093-102.
    PubMed     Text format     Abstract available


  106. HUO YR, Huang Y, Liauw W, Zhao J, et al
    Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy.
    Anticancer Res. 2016;36:1041-9.
    PubMed     Text format     Abstract available


  107. SHIBUTANI M, Maeda K, Nagahara H, Iseki Y, et al
    Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer.
    Anticancer Res. 2016;36:995-1001.
    PubMed     Text format     Abstract available


  108. WU BO, Jiang WG, Zhou D, Cui YX, et al
    Knockdown of EPHA1 by CRISPR/CAS9 Promotes Adhesion and Motility of HRT18 Colorectal Carcinoma Cells.
    Anticancer Res. 2016;36:1211-9.
    PubMed     Text format     Abstract available


  109. HUANG Y, Alzahrani NA, Chua TC, Huo YR, et al
    Clinical Outcomes of Patients with Extensive Peritoneal Carcinomatosis Following Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
    Anticancer Res. 2016;36:1033-40.
    PubMed     Text format     Abstract available


  110. ISHIKAWA T, Uetake H, Murotani K, Kobunai T, et al
    Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.
    Anticancer Res. 2016;36:853-60.
    PubMed     Text format     Abstract available


  111. HADAC JN, Miller DD, Grimes IC, Clipson L, et al
    Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.
    Anticancer Res. 2016;36:845-52.
    PubMed     Text format     Abstract available


    February 2016
  112. MIYAMOTO Y, Sakamoto Y, Ohuchi M, Tokunaga R, et al
    Orbital Apex Syndrome Caused by Invasive Aspergillosis as an Adverse Effect of Systemic Chemotherapy for Metastatic Colorectal Cancer: a Case Report.
    Anticancer Res. 2016;36:821-3.
    PubMed     Text format     Abstract available


  113. OGAWA M, Ichiba N, Watanabe M, Yanaga K, et al
    The Usefulness of Diffusion MRI in Detection of Lymph Node Metastases of Colorectal Cancer.
    Anticancer Res. 2016;36:815-9.
    PubMed     Text format     Abstract available


  114. LACZMANSKA I, Karpinski P, Gil J, Laczmanski L, et al
    High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
    Anticancer Res. 2016;36:677-81.
    PubMed     Text format     Abstract available


  115. SAKATANI A, Fujiya M, Ueno N, Kashima S, et al
    Polyphosphate Derived from Lactobacillus brevis Inhibits Colon Cancer Progression Through Induction of Cell Apoptosis.
    Anticancer Res. 2016;36:591-8.
    PubMed     Text format     Abstract available


  116. JIANG X, Kim KJ, Ha T, Lee SH, et al
    Potential Dual Role of Activating Transcription Factor 3 in Colorectal Cancer.
    Anticancer Res. 2016;36:509-16.
    PubMed     Text format     Abstract available


  117. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


  118. JUNGINGER T, Goenner U, Hitzler M, Trinh TT, et al
    Influence of Local Recurrence and Distant Metastasis on Prognosis After Local Excision of Rectal Carcinoma.
    Anticancer Res. 2016;36:763-8.
    PubMed     Text format     Abstract available


  119. UEKI T, Manabe T, Inoue S, Ienaga J, et al
    A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
    Anticancer Res. 2016;36:741-7.
    PubMed     Text format     Abstract available


    January 2016
  120. LUMACHI F, Chiara GB, Tozzoli R, Del Contea A, et al
    Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis.
    Anticancer Res. 2016;36:13-9.
    PubMed     Text format     Abstract available


  121. KAKU Y, Tsuchiya A, Shimizu T, Tanaka A, et al
    HUHS1015 Suppresses Colonic Cancer Growth by Inducing Necrosis and Apoptosis in Association with Mitochondrial Damage.
    Anticancer Res. 2016;36:39-48.
    PubMed     Text format     Abstract available


  122. CHEN J, Han M, Saif MW
    TAS-102 an Emerging Oral Fluoropyrimidine.
    Anticancer Res. 2016;36:21-6.
    PubMed     Text format     Abstract available


  123. KAWAHARA H, Misawa T, Watanabe K, Hojo S, et al
    Feasibility of Single-incision Laparoscopic Surgery plus One Assist Port for Anterior Resection.
    Anticancer Res. 2016;36:467-9.
    PubMed     Text format     Abstract available


  124. ZEZULOVA M, Bartouskova M, Hlidkova E, Juranova J, et al
    Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients with Rectal Carcinoma Treated with Chemoradiation.
    Anticancer Res. 2016;36:287-92.
    PubMed     Text format     Abstract available


    December 2015
  125. THOMAS SA, Tomeh N, Theard S
    Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
    Anticancer Res. 2015;35:6761-3.
    PubMed     Text format     Abstract available


  126. KAZAMA S, Kishikawa J, Yasuda K, Otani K, et al
    CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer.
    Anticancer Res. 2015;35:6599-605.
    PubMed     Text format     Abstract available


  127. UEDA M, Iguchi T, Komatsu H, Kidogami S, et al
    Clinical Significance of Expression of Nephroblastoma Overexpressed (NOV) in Patients with Colorectal Cancer.
    Anticancer Res. 2015;35:6591-7.
    PubMed     Text format     Abstract available


  128. KOBAYASHI T, Masaki T, Nozaki E, Sugiyama M, et al
    Microarray Analysis of Gene Expression at the Tumor Front of Colon Cancer.
    Anticancer Res. 2015;35:6577-81.
    PubMed     Text format     Abstract available


  129. VAN WYK HC, Foulis AK, Roxburgh CS, Orange C, et al
    Comparison of Methods to Identify Lymphatic and Blood Vessel Invasion and their Prognostic Value in Patients with Primary Operable Colorectal Cancer.
    Anticancer Res. 2015;35:6457-63.
    PubMed     Text format     Abstract available


    November 2015
  130. KLAIRMONT M, Kopkash K, Favuzza J, Hill M, et al
    Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus.
    Anticancer Res. 2015;35:6159-62.
    PubMed     Text format     Abstract available


  131. RAZIK E, Kobierzycki C, Grzegrzolka J, Podhorska-Okolow M, et al
    Plasminogen Activation System in Rectal Adenocarcinoma.
    Anticancer Res. 2015;35:6009-15.
    PubMed     Text format     Abstract available


  132. PHAM MH, Delestre L, Dewitte A, Wattez N, et al
    Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
    Anticancer Res. 2015;35:5983-91.
    PubMed     Text format     Abstract available


  133. VAN MOURIK TR, Lappchen T, Rossin R, VAN Beijnum JR, et al
    Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis.
    Anticancer Res. 2015;35:5945-54.
    PubMed     Text format     Abstract available


    September 2015
  134. NUKATSUKA M, Nakagawa F, Takechi T
    Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Anticancer Res. 2015;35:4605-15.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: